April 2025 exceptional surveillance of suspected cancer: recognition and referral (NICE guideline NG12)
In April 2025, we reviewed this guideline in response to a series of NHS England National cancer programme reviews that looked at opportunities for earlier diagnosis, including for myeloma.
Surveillance decision
We decided to update the section on myeloma to include serum protein electrophesis and serum free light chain testing in the initial diagnostic blood tests. We also recommended that, if available, serum free light chain testing should be offered or considered instead of Bence–Jones urine testing.
This page was last updated: